Finance

Beta
Lists
GL9:FRA
Glanbia plc
€23,20
+7,11%
(+1,54) 1D
12 Jun., 11:41:31 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GL9...
Open
€21,56
High
€23,40
Low
€21,56
Mkt. cap
5,84 mjd
Avg. vol.
211,00
Volume
160,00
Dividend
2,02%
Quarterly dividend
€0,12
Ex-dividend date
19 Mrt. 2026
P/E ratio
36,94
52-wk high
€23,40
52-wk low
€12,10
EPS
€0,63
No. of employees
5 k
Open
€21,56
High
€23,40
Low
€21,56
Mkt. cap
5,84 mjd
Avg. vol.
211,00
Volume
160,00
Dividend
2,02%
Quarterly dividend
€0,12
Ex-dividend date
19 Mrt. 2026
P/E ratio
36,94
52-wk high
€23,40
52-wk low
€12,10
EPS
€0,63
No. of employees
5 k
News stories
From sources across the web
Profile
Glanbia plc is an Irish multinational nutrition company that owns several consumer brands that produce products such as food supplements and ingredients businesses. Glanbia is headquartered in Kilkenny, Ireland with over 5,500 employees in over 30 countries around the world. Glanbia’s consumer brands and ingredients are sold or distributed in over 130 countries. North America is the company’s largest market, and it also has a presence in Europe, Middle East, Asia-Pacific and Latin America. Glanbia's primary listing is on Euronext Dublin. Glanbia comprises three divisions: Glanbia Nutritionals, Glanbia Performance Nutrition and Joint Ventures. Given the company's origins in the co-operative movement, farmer-suppliers of the company retain a significant interest in the company. Tirlán remains the largest shareholder in Glanbia plc. as of 2022 and retains the right to nominate a number of non-executive directors to the board of the company in line with their mutual Relationship Agreement. Wikipedia
About Glanbia plc
CEOHugh McGuire
Employees4,96 k
Founded1997
Headquarters-
Sector-
Websiteglanbia.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Apr. 2025
Jul. 2025
Okt. 2025
Jan. 2026
Revenue
963,35 m
963,35 m
1,01 mjd
1,01 mjd
Cost of goods sold
700,30 m
700,30 m
742,10 m
742,10 m
Cost of revenue
700,30 m
700,30 m
742,10 m
742,10 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
162,20 m
162,20 m
155,35 m
155,35 m
Operating expense
180,60 m
180,60 m
175,05 m
175,05 m
Total operating expenses
880,90 m
880,90 m
917,15 m
917,15 m
Operating income
82,45 m
82,45 m
92,70 m
92,70 m
Other non operating income
-750,00 k
-750,00 k
-550,00 k
-550,00 k
EBT including unusual items
57,25 m
57,25 m
47,35 m
47,35 m
EBT excluding unusual items
77,35 m
77,35 m
88,65 m
88,65 m
Income tax expense
7,55 m
7,55 m
5,40 m
5,40 m
Effective tax rate
13,19%
13,19%
11,40%
11,40%
Other operating expenses
-900,00 k
-900,00 k
1,35 m
1,35 m
Net income
49,70 m
49,70 m
41,95 m
41,95 m
Net profit margin
5,16%
5,16%
4,15%
4,15%
Earnings per share
-
-
-
-
Interest and investment income
550,00 k
550,00 k
650,00 k
650,00 k
Interest expense
-6,60 m
-6,60 m
-8,00 m
-8,00 m
Net interest expenses
-6,05 m
-6,05 m
-7,35 m
-7,35 m
Depreciation and amortization charges
-
-
-
-
EBITDA
115,05 m
115,05 m
110,95 m
110,95 m
Gain or loss from assets sale
4,35 m
4,35 m
18,70 m
18,70 m
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer